Best Life Sciences Companies in Capital Region of Denmark, Denmark

Developer of antibody-drug conjugates for the treatment of cancer. The company's drug is developed to target specialized endocytic receptors that are uPARAP and endo180. It allows targeted therapy in cancer, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Funding rounds

• Apr 2026Series C$75M
• Nov 2024Series B$135M
• May 2024Series A$17.4M
• Apr 2023Series A$33.9M

Founders & team

Niels BehrendtCo-FounderLars EngelholmCo-FounderMichael PehlCEO

Investors

Gilde Healthcare, RA Capital Management, Ysios Capital, Healthcap, Novo Holdings, Dawn Biopharma

Tech stack

CdnjsCloudflareCookiebotDiviFont AwesomeGoogle Analytics

Developer of preventative treatments for rare bleeding and thrombotic disorders. It develops novel therapies designed to modulate the body's clotting pathway, using antibodies to either stabilize or inhibit clotting factors. This approach addresses a significant unmet need for patients with less common disorders, offering prophylactic treatments and potential functional cures to prevent life-threatening complications. The company's pipeline includes several therapeutic candidates targeting various rare clotting disorders.

Developer of biological solutions to reduce bacterial gastrointestinal infections. The company has developed a Virulence Inactivating protein and Ablacto for targeting specific pathogens to reduce the risk of gastrointestinal infections in animals and humans.

Funding rounds

• Jan 2026Series B$35.1M
• Aug 2023Series A$33M
• Aug 2022Grant (prize money)$5M
• Apr 2021Seed$8.5M

Founders & team

Sandra ThraneCo-Founder & CSOAndreas LaustsenCo-Founder & CTOMads LaustsenCo-Founder

Investors

Gates, Novo Holdings, ATHOS, Cross Border Impact Ventures, Danmarks Eksport og Investeringsfond, Selfinvest

Tech stack

Apache Http ServerComplianzContact Form 7Core-JsElementorGoogle Analytics

Kvantify is a company that provides off-the-shelf, sector-specific solutions for the financial services and life sciences industries. They use cutting-edge algorithms and quantum computing technology to address hard computational challenges. Kvantify aims to democratize access to advanced computing technology and help businesses contribute to a better future.

Funding rounds

• Mar 2026Seed$8.1M
• Jul 2024Seed$10.7M
• Feb 2023Grant (prize money)$713K
• Grant (prize money)—

Founders & team

Allan GronlundCo-Founder & CTONikolaj ZinnerCo-FounderHans KnudsenCo-Founder

Investors

EIC Fund, Dreamcraft Ventures, Lundbeck Foundation, 2degrees, Redstone, 2xN

Tech stack

Amazon SesAmazon Web ServicesCookiebotEmotionGodaddyGoogle Analytics

Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely. The company focuses on treating difficult conditions like multidrug-resistant infections, cystic fibrosis, IBD, and certain cancers by engineering the human microbiome.

Funding rounds

• Aug 2025Series B$40.6M
• Dec 2024Venture Debt$21.1M
• Jan 2024Series B$11.9M
• Jun 2022Series A$8.4M

Founders & team

Morten SommerCo-FounderJasper ClubeCo-FounderChristian GroendahlCo-Founder and CEO

Investors

CARB-X, Lundbeck Foundation, Life Sciences Partners, Wellington Partners Venture Capital, North-East, EQT

Tech stack

Squarespace CommerceSquarespaceYoutubeAnimate.CssStimulusCloudflare

Developer of therapeutic vaccines against cancer and infectious diseases. The company has proprietary poxviral-based vaccine platform technologies, to develop medicines that address a wide variety of infectious diseases and cancers. The company has developed a pipeline for Smallpox, RSV, COVID-19 and Immuno-oncology.

Developer of supplement for the management of alcohol intolerance. The company is developing a supplement an oral form, that can degrade ingested alcohol before it hits the bloodstream that aims to help people with alcohol intolerance without experiencing side effects like flushing, rapid heartbeat, and nausea.

Funding rounds

• May 2026Seed$1.7M

Founders & team

Mads MikkelsenCo-Founder & CEOMikkel PrechtCo-FounderJeppe MikkelsenCo-Founder & CEO

Investors

Ada Ventures, Delphinus Venture Capital, Antler, Manigoff Invest

Developer of peptide-based therapies for obesity and cardiometabolic disorders. It offers optimized analogues of naturally occurring GIP receptor inhibitors to induce weight loss and treat obesity without common gastrointestinal side effects.

Funding rounds

• Dec 2024Series A$84.1M
• May 2022Seed$503.4K
• Jun 2021Seed$1.6M
• Oct 2018Seed$1.2M

Founders & team

Alexander Sparre-UlrichCo-Founder & COOJoerg MoellerCEO

Investors

Versant Ventures, Novo Holdings, SR One, Pictet Group, Danmarks Eksport og Investeringsfond, Dawn Biopharma

Provider of immune monitoring reagents and services for research and clinical use. It offers a portfolio of products, including dextramer reagents for flow cytometry and other applications, Klickmer reagents, and custom solutions. The products are used to detect and characterize antigen specific immune cells, supporting research in areas such as vaccine development, cell therapy, and infectious disease. It also provides services such as custom allele production and proficiency testing. Its offerings enable researchers and clinicians to gain a deeper understanding of the immune response in various contexts.It provides a range of products and services such as Dextramer and dcode MHC multimers for detailed immune profiling, clinical grade reagents, monomers and U- Load reagents, techincal and scientfic support, and more.

Funding rounds

• Feb 2025Series A$290.6K
• Feb 2024Series A$305.1K
• Mar 2023Series A$245.5K
• Apr 2022Series A$249K

Founders & team

Liselotte BrixCSOPatrik DahlenChief Executive Officer

Tech stack

BootstrapCart FunctionalityCdnjsCloudflareCloudflare Bot ManagementCloudflare Browser Insights

Provider of technology for oral delivery of biologics. The solution provided is BIONND provides a solution for the dosing of biologics in a standard oral capsule. The platform delivers biologics by the oral route in a standard capsule by directing the biologic drug molecule inside the intestinal wall for release to the body. With the release of the drug molecule inside the intestinal wall, the usual barriers are circumvented.

Founders & team

Lars ChristiansenFounderKarsten LindhardtFounder & CEO

Investors

MEGATREND INVEST, HTGF, EIT Health, Evonik, Verve Ventures, Sanner Ventures

Provider of drug discovery platform to develop multiple therapeutics. The company utilizes novel macrocyclic chemistry and computational platforms for high-throughput drug discovery and develop drug candidates for challenging targets.

Funding rounds

• Jan 2025Series A$92.8M
• Feb 2024Seed$32.9M

Founders & team

Sevan HabeshianCo-FounderMorten GraugaardCEO

Investors

Novo Holdings, Forbion, New Enterprise Associates, Lilly, Cormorant Asset Management, Danmarks Eksport og Investeringsfond

Developer of immunotherapies for the treatment of a variety of cancers. The company combines expertise in antibody development and complement research to refine the BiCE technology and creates a new type of immunotherapy for the treatment of a variety of cancers.